[의학신문·일간보사=김민지 기자] Ahn Kook Pharm (CEO Eo Jin) held a total of three web symposiums on the 9th, 17th and 23rd with the theme of’improving the quality of sleep without tolerance or habits’ in relation to the hypnotic sedative’Melatonin’ It was revealed on the 28th.
 |
Ahn Kook Pharm’s’Sirkaton Pr Sustained-release Tablet’ is a melatonin formulation approved in Korea.
Ahn Kook Pharm held a symposium online in consideration of the COVID-19 situation. Through this web symposium, the company re-examined the importance of improving sleep quality, contributing to the clinical practice guidelines for insomnia and the discontinuation of psychotropic sleeping pills, and also introduced the importance of improving sleep quality by patient case.
Professor Won-koo Lee of the Department of Neurology at Kosin University, who presented at this web symposium, said, “Through improvement of sleep quality, the risk of developing degenerative brain diseases such as Alzheimer’s can be reduced.” Said.
PM Ahn Kook Pharm said, “Patients who have to take melatonin have not received active treatment due to the burden of drug prices, but through the release of the Circaton PIR sustained-release tablet, it is possible to actively treat patients with insufficient melatonin hormone concentration without burdening the drug price.” Through quality improvement, we can improve the quality of life for menopausal women over the age of 55, obese patients, and patients with mild cognitive impairment.”